The prevalence of mutations in CEBPA ranges between 5 and 10 [8], therefore the 1010 CEBPA-mutant patients investigated in this study correspond to a total of 10.000–20.000 adult patients with AML. The gene discussed is CEBPA; the disease is acute myeloid leukemia.